Altimmune, Inc. (ALT) vs Oculis Holding AG (OCS)
A side-by-side comparison of Altimmune, Inc. and Oculis Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OCS
Oculis Holding AG
$8.72HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ALT vs OCS
growth of $100 · dividends reinvested · last 5yALT -81.2% (-28.4%/yr)OCS -11.8% (-2.5%/yr)OCS compounded faster over this window
ALT OCS
ALT vs OCS: by the numbers
- •ALT is the larger company ($519M vs $499M market cap).
- •Both run net losses; OCS's is the smaller (-32724.20% vs -296000.00% net margin).
Metrics side by side
Valuation
| Metric | ALT | OCS |
|---|---|---|
| P/S ratio | 16749.86 | 1634.02 |
| P/B ratio | 1.09 | 1.84 |
Profitability
| Metric | ALT | OCS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -230460.98% | 0.00% |
| Net margin | -296000.00% | -32724.20% |
| ROE | -19.35% | -36.79% |
| ROIC | -19.47% | -39.63% |
Growth (annualized)
| Metric | ALT | OCS |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | N/A |
| Total return CAGR (5Y) | -25.30% | -2.41% |
Frequently asked
- How have ALT and OCS total returns compared?
- Over the past 5 years, ALT delivered -25.30% and OCS delivered -2.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.